17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy

Revision as of 10:14, 13 October 2022 by Jose Loyola (talk | contribs)
Jump to navigation Jump to search

17-beta-hydroxysteroid dehydrogenase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating 17-beta-hydroxysteroid dehydrogenase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Molecular Genetic Studies

Genotyping

X Ray

CT

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy

CDC on 17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy

17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy in the news

Blogs on 17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy

Directions to Hospitals Treating 17-beta-hydroxysteroid dehydrogenase deficiency

Risk calculators and risk factors for 17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdulkerim Yassin, M.B.B.S[2]

Overview

Surgical therapy is guided by the risk of germ cell tumor development and to allow for proper gender assignment.

Surgical therapy

  • Patients with 17-beta hydroxysteroid dehydrogenase deficiency have moderate risk of germ cell tumor.[1]
  • These patients must be monitored closely, as the development of germ cell tumor requires the removal of the gonads.
  • Surgery can also be used to treat anatomic changes due to the hormonal disorder. Patients with this disease may present with ambiguous or female genitalia, despite most of them developing male gender identity.
  • Some studies have suggested that early surgical treatment may improve outcomes. Feminising genitoplasty usually requires less surgery interventions than masculinizing genitoplasty. Outcomes vary greatly in both cases. Many patients may present with risk of neoplasia associated with the neovagina, while regarding the masculinizing genitoplasty's results are heavily associated with the amount of erectile tissue and degree of hypospadias.[1]

References

  1. 1.0 1.1 Melnik B, Hollmann J, Hofmann U, Yuh MS, Plewig G (1990). "Lipid composition of outer stratum corneum and nails in atopic and control subjects". Arch Dermatol Res. 282 (8): 549–51. doi:10.1007/BF00371952. PMID 2082839.

Template:WH Template:WS